Biotest AG 是一家總部位於德國的生物技術公司,公司總部設於黑森邦德賴艾希,目前僱用2,495名全職員工。Biotest AG 是德國知名的血漿蛋白與生物製藥供應商,其業務鏈從臨床前及臨床開發延伸至全球行銷與分銷,主要專注於臨床免疫學、血液學以及重症醫學領域。公司研發、生產並銷售基於人類血漿的免疫球蛋白、凝血因子與白蛋白,應用於免疫系統與造血系統疾病的治療。此外,公司亦運用重組技術開發針對漿細胞癌與全身性紅斑狼瘡適應症的單株抗體。
Based on comprehensive analyst evaluations, we have synthesized critical insights from expert assessments to outline a cautious outlook for BIESF. Analysts note deteriorating fundamentals and challenging market sentiment, indicating potential downside risks in the near term. Following this expert analysis, we adopt a bearish stance on this stock. Our conclusion: BIESF is a Sell candidate.
BIESF stock price ended at $32 on 星期一, after dropping NaN%
On the latest trading day Mar 10, 2025, the stock price of BIESF fell by NaN%, dropping from $32.00 to $32.00. During the session, the stock saw a volatility of 0.00%, with prices oscillating between a daily low of $32.00 and a high of $32.00. On the latest trading day, the trading volume for BIESF decreased by -- shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 100 shares were traded, with a market value of approximately $633.1M.